Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP477306.RAt-QhW2_Wk7DbRN2z7Cs8cwgzkeEmBnEBCOen320M5hU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP477306.RAt-QhW2_Wk7DbRN2z7Cs8cwgzkeEmBnEBCOen320M5hU130_assertion type Assertion NP477306.RAt-QhW2_Wk7DbRN2z7Cs8cwgzkeEmBnEBCOen320M5hU130_head.
- NP477306.RAt-QhW2_Wk7DbRN2z7Cs8cwgzkeEmBnEBCOen320M5hU130_assertion description "[Enrolled in the study were 203 patients with chronic active hepatitis C. They were all given: interferon alpha-2a (3 MU subcutaneously thrice a week) and ursodeoxycholic acid (10 mg/kg/day) for 9 months.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP477306.RAt-QhW2_Wk7DbRN2z7Cs8cwgzkeEmBnEBCOen320M5hU130_provenance.
- NP477306.RAt-QhW2_Wk7DbRN2z7Cs8cwgzkeEmBnEBCOen320M5hU130_assertion evidence source_evidence_literature NP477306.RAt-QhW2_Wk7DbRN2z7Cs8cwgzkeEmBnEBCOen320M5hU130_provenance.
- NP477306.RAt-QhW2_Wk7DbRN2z7Cs8cwgzkeEmBnEBCOen320M5hU130_assertion SIO_000772 10975752 NP477306.RAt-QhW2_Wk7DbRN2z7Cs8cwgzkeEmBnEBCOen320M5hU130_provenance.
- NP477306.RAt-QhW2_Wk7DbRN2z7Cs8cwgzkeEmBnEBCOen320M5hU130_assertion wasDerivedFrom befree-20150227 NP477306.RAt-QhW2_Wk7DbRN2z7Cs8cwgzkeEmBnEBCOen320M5hU130_provenance.
- NP477306.RAt-QhW2_Wk7DbRN2z7Cs8cwgzkeEmBnEBCOen320M5hU130_assertion wasGeneratedBy ECO_0000203 NP477306.RAt-QhW2_Wk7DbRN2z7Cs8cwgzkeEmBnEBCOen320M5hU130_provenance.